Grifols (GRFS) Competitors $9.91 +0.33 (+3.39%) As of 10:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRFS vs. BNTX, TEVA, SMMT, GMAB, VTRS, ASND, RDY, QGEN, BBIO, and MRNAShould you be buying Grifols stock or one of its competitors? The main competitors of Grifols include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), BridgeBio Pharma (BBIO), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry. Grifols vs. Its Competitors BioNTech Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Viatris Ascendis Pharma A/S Dr. Reddy's Laboratories QIAGEN BridgeBio Pharma Moderna Grifols (NASDAQ:GRFS) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations. Is GRFS or BNTX more profitable? Grifols has a net margin of 0.00% compared to BioNTech's net margin of -12.20%. Grifols' return on equity of 0.00% beat BioNTech's return on equity.Company Net Margins Return on Equity Return on Assets GrifolsN/A N/A N/A BioNTech -12.20%-1.84%-1.59% Does the media favor GRFS or BNTX? In the previous week, BioNTech had 9 more articles in the media than Grifols. MarketBeat recorded 11 mentions for BioNTech and 2 mentions for Grifols. Grifols' average media sentiment score of 1.41 beat BioNTech's score of 1.19 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer GRFS or BNTX? Grifols presently has a consensus target price of $10.30, indicating a potential upside of 4.29%. BioNTech has a consensus target price of $135.80, indicating a potential upside of 35.20%. Given BioNTech's stronger consensus rating and higher possible upside, analysts plainly believe BioNTech is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.60BioNTech 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.76 Is GRFS or BNTX a better dividend stock? Grifols pays an annual dividend of $0.14 per share and has a dividend yield of 1.4%. BioNTech pays an annual dividend of $1.53 per share and has a dividend yield of 1.5%. Grifols pays out 12.0% of its earnings in the form of a dividend. BioNTech pays out -95.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. BioNTech is clearly the better dividend stock, given its higher yield and lower payout ratio. Do insiders & institutionals believe in GRFS or BNTX? 15.5% of BioNTech shares are held by institutional investors. 0.2% of Grifols shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has stronger earnings & valuation, GRFS or BNTX? Grifols has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$7.81B0.87$169.80M$1.178.44BioNTech$2.88B8.39-$719.92M-$1.60-62.78 Which has more volatility & risk, GRFS or BNTX? Grifols has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. SummaryBioNTech beats Grifols on 10 of the 19 factors compared between the two stocks. Get Grifols News Delivered to You Automatically Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRFS vs. The Competition Export to ExcelMetricGrifolsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.80B$2.53B$5.75B$9.83BDividend Yield1.43%48.51%6.66%4.49%P/E Ratio8.4522.6782.7626.42Price / Sales0.87525.52505.21162.19Price / Cash10.6526.3325.7028.92Price / Book0.796.8210.816.53Net Income$169.80M$32.94M$3.28B$266.04M7 Day Performance0.06%0.42%-0.28%-1.05%1 Month Performance-7.87%5.86%8.49%4.17%1 Year Performance6.19%-0.59%50.80%23.95% Grifols Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRFSGrifols3.9234 of 5 stars$9.92+3.4%$10.30+3.9%+2.2%$6.81B$7.81B8.4723,822Positive NewsBNTXBioNTech1.9453 of 5 stars$100.00-1.9%$135.80+35.8%+14.1%$24.04B$2.98B-62.506,772Positive NewsTEVATeva Pharmaceutical Industries3.5133 of 5 stars$18.41+2.0%$24.71+34.3%+1.3%$21.08B$16.54B-115.0436,830News CoveragePositive NewsSMMTSummit Therapeutics3.3331 of 5 stars$23.70-2.9%$33.31+40.5%+86.7%$17.61B$700K-23.47110News CoverageAnalyst ForecastOptions VolumeGMABGenmab A/S4.045 of 5 stars$24.87-1.0%$37.60+51.2%-1.2%$15.96B$3.12B12.502,682VTRSViatris1.7965 of 5 stars$10.55+1.3%$10.40-1.4%-11.3%$12.30B$14.74B-3.6432,000ASNDAscendis Pharma A/S3.4465 of 5 stars$194.27+0.2%$243.36+25.3%+48.5%$11.89B$393.54M-37.651,017News CoveragePositive NewsAnalyst ForecastRDYDr. Reddy's Laboratories2.792 of 5 stars$14.20-0.1%$16.95+19.4%-12.6%$11.86B$3.81B21.5127,811Positive NewsQGENQIAGEN4.2625 of 5 stars$46.53+0.9%$49.69+6.8%+8.4%$10.34B$1.98B27.495,765Positive NewsBBIOBridgeBio Pharma4.1598 of 5 stars$51.76-1.5%$62.18+20.1%+80.4%$9.89B$221.90M-12.66400News CoveragePositive NewsAnalyst ForecastMRNAModerna4.5401 of 5 stars$24.09-1.6%$42.88+78.0%-67.0%$9.37B$3.24B-3.205,800 Related Companies and Tools Related Companies BNTX Alternatives TEVA Alternatives SMMT Alternatives GMAB Alternatives VTRS Alternatives ASND Alternatives RDY Alternatives QGEN Alternatives BBIO Alternatives MRNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRFS) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRFS Stock Alerts